TG Therapeutics Equity 2024

TG Therapeutics Aktienanalyse

What does TG Therapeutics do?

TG Therapeutics Inc is a biopharmaceutical company based in New York City, USA. The company was founded in 2012 and focuses on the development and commercialization of innovative therapy options for various types of cancer and autoimmune diseases. TG Therapeutics was founded as a result of a collaboration between Michael S. Weiss, an experienced investment banker and biotechnology manager, and Laurence N. Charous, an oncologist and clinical researcher. The company has roots in two predecessor companies: Manhattan Pharmaceuticals and LFB Biotechnologies. Both had failed, and TG rose from their remains. TG Therapeutics' business model is to develop a new therapy option by combining drugs of different drug classes that target the needs of patients with specific cancer conditions. The dual blockade approach, which simultaneously inhibits various signaling pathways that sustain tumor cells, is particularly promising. TG Therapeutics operates a diversified portfolio strategy and has several drug candidates in different stages of development for numerous cancer conditions, including diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma, as well as autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. TG Therapeutics' main products for cancer treatments currently are umapalisib and umbralisib, both of which are PI3K delta inhibitors and are being developed for the treatment of non-Hodgkin lymphomas and chronic lymphocytic leukemia. TG-1101 (Ublituximab) is a CD20-targeted antibody therapy used in lymphomas and autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. TG Therapeutics' research and development efforts are driven by an experienced team of oncologists and scientists, including CEO Michael S. Weiss. The company maintains close relationships with academic institutions and research facilities. TG Therapeutics holds a broad patent portfolio covering technologies and compounds that can be used in cancer and autoimmune disease treatment. In 2020, TG Therapeutics' revenue reached approximately $109 million, compared to $14 million in the previous year. This increase in revenue was due to the sales of umbralisib. However, the company has not yet received FDA approval for any of its drugs in the US. TG Therapeutics expects that the future success of the company will be based on the clinical activity of its pipeline, market acceptance of its products, and successful completion of studies and regulatory approvals. As of December 31, 2020, TG Therapeutics had 248 employees. The company's leading body, the board of directors, consists of an experienced team of executives and advisors, including Chairman and CEO Michael S. Weiss, CFO Sean A. Power, CMO Adam D. Feuerstein, and COO Scott T. Smith. TG Therapeutics has had a tumultuous past, but the company can now look forward to a promising pipeline and a very strong financial position. The research and development of this biopharmaceutical company are promising, and it remains to be seen which of the research products will actually break through and be introduced to the market. TG Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing TG Therapeutics's Equity

TG Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding TG Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating TG Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

TG Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in TG Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about TG Therapeutics stock

What is the equity of TG Therapeutics this year?

TG Therapeutics has equity of 160.5 M USD this year.

What was the equity of TG Therapeutics compared to the previous year?

The equity of TG Therapeutics has increased/decreased by 173.89% increased compared to the previous year.

What impact does a high equity have on investors of TG Therapeutics?

A high equity is advantageous for investors of TG Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of TG Therapeutics?

A low equity can be a risk for investors of TG Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of TG Therapeutics affect the company?

An increase in equity of TG Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of TG Therapeutics affect the company?

A reduction in equity of TG Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of TG Therapeutics?

Some factors that can affect the equity of TG Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of TG Therapeutics so important for investors?

The equity of TG Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can TG Therapeutics take to change the equity?

To change equity, TG Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does TG Therapeutics pay?

Over the past 12 months, TG Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, TG Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of TG Therapeutics?

The current dividend yield of TG Therapeutics is .

When does TG Therapeutics pay dividends?

TG Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of TG Therapeutics?

TG Therapeutics paid dividends every year for the past 0 years.

What is the dividend of TG Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is TG Therapeutics located?

TG Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von TG Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of TG Therapeutics from 7/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/5/2024.

When did TG Therapeutics pay the last dividend?

The last dividend was paid out on 7/5/2024.

What was the dividend of TG Therapeutics in the year 2023?

In the year 2023, TG Therapeutics distributed 0 USD as dividends.

In which currency does TG Therapeutics pay out the dividend?

The dividends of TG Therapeutics are distributed in USD.